The European Medicines Agency’s CHMP has recommended approval of Gilead Sciences’ lenacapavir, a twice-yearly injection for preventing HIV infection.

A new report examines why linked data is essential to advancing healthcare and improving outcomes for patients.

The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas.

The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.

Sarepta Therapeutics is refusing to pull its gene therapy Elevidys (delandistrogene moxeparvovec), despite a request from the FDA.

Growing budgetary pressure is a central theme in France as it prepares for the publication of the government's 2026 Social Security Finance Bill (PLFSS).

The UK and India’s new £4.8bn free trade agreement (FTA) is expected to allow new opportunities for Indian medical device and pharmaceutical manufacturers.

Sarepta said it accepts the CHMP decision on Elevidys, while partner Roche said it will continue working with the EMA.

The clinical trial industry has long recognized the importance of standardization in driving efficiency and ensuring data quality. Efforts ...

In today’s tech-driven landscape, it seems like every software solution in the clinical industry needs to have some AI ...